PolyPid Ltd PYPD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.42
- Day Range
- $5.16–5.45
- 52-Week Range
- $3.06–5.62
- Bid/Ask
- $5.23 / $5.80
- Shares Outstanding
- 19.17M
- Market Cap
- $100.28M
- Volume/Avg
- 256,613 / 137,218
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 75
- Website
- https://www.polypid.com
Valuation
|
Metric
|
PYPD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 11.64 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PYPD
|
|---|---|
Quick Ratio | 1.55 |
Current Ratio | 1.78 |
Interest Coverage | −210.54 |
Quick Ratio
PYPD
Profitability
|
Metric
|
PYPD
|
|---|---|
Return on Assets (Normalized) | −136.88% |
Return on Equity (Normalized) | −301.98% |
Return on Invested Capital (Normalized) | −202.47% |
Return on Assets
PYPD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$@W#VKY | LOCK|Ms<>B | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|J%HSs&> | LOCK|#Q@>J | $70B | |||
| argenx SE ADR
ARGX
| LOCK|$Kp?^vb | LOCK|Y? | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Dsv!TVX | LOCK|vZ&> | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#Xbn#> | LOCK|k? | $36B | |||
| Moderna Inc
MRNA
| LOCK|%#K?J? | LOCK|&$ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$N<CVbW | LOCK|%>&?B | $25B | |||
| Incyte Corp
INCY
| LOCK|Y>&wv% | LOCK|Jw! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&?lm<m | LOCK|p@x | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|ht@#mJ# | LOCK|$@ | $17B |
United States